Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas

Glioma Clinical Trial

— LoG-Glio  

Official title:

Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas: The LOG-Glio-Project

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02686229
• Other study ID #: LoG-Glio
• Status: Recruiting
• Start date: November 15, 2015
• Est. completion date: December 2036

Study information

• Verified date: May 2023
• Source: University of Ulm
• Contact: Jan Coburge, MD
• Phone: 082219628858
• Email: jan.coburger[@]uni-ulm.de
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The LoG-Glio-Registry is based on a network of german hospitals gathering radiological, clinical, epidemiological and molecular data on all patients diagnosed with a low grade glioma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: December 2036
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with radiological suspected diagnosis of a low grade glioma

• Age = 18 years. There is no upper age limit.

Exclusion Criteria:

• Severe neurological or psychiatric disorder interfering with ability to give an informed consent

• No consent for registration, storage and processing of the individual disease characteristics and course as well as information of the family physician about study participation

• No consent for bio-banking of patient's biological specimens and performance of analyses on stored material.

Related Conditions & MeSH terms

• Glioma

Intervention

Other:
• no interventions

Locations

Country	Name	City	State
Germany	University of Ulm	Ulm

Sponsors (2)

Lead Sponsor	Collaborator
University of Ulm	Charite University, Berlin, Germany

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS)		5yrs
Primary	Overall survival (OS)		15yrs
Secondary	Extent of tumor resection	calculated based on volumetric assessement of tumor in cm³ and residual tumor in pre and postoperative MRI	3yrs
Secondary	Quality of life (QoL) assessed by the EORTC QLQ C-30/BN-20. (European Organisation for Research and Treatment of Cancer Quality of Life Questionaire C-30		5yrs